Related Experiment Video
Updated: Jan 15, 2026
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
Defining critical symptom parameters for an ePRO-based management pathway during systemic treatment for advanced
Xin Shelley Wang1, Mariela Blum Murphy2, Shu-En Shen3
1Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit, Houston, TX, 77030, USA. xswang@mdanderson.org.
Purpose:
Establishing a care pathway based on electronic patient-reported outcomes (ePROs) is necessary to effectively assess and manage outpatients undergoing active treatment. This study investigated symptom burden in patients with advanced upper gastrointestinal (UGI) cancer and the characteristics needed for implementing an ePRO system to monitor these patients.
Methods:
Patients undergoing systemic therapy for metastatic UGI cancer rated symptom severity and functional impairment by completing the MD Anderson Symptom Inventory for Gastrointestinal Cancer (MDASI-GI) repeatedly for 12 months. Group-based trajectory analysis classified patients into a high-severity symptom group if their symptoms were consistently rated higher than other patients' symptoms over time. A composite score of the most-severe symptoms was calculated and evaluated.
Results:
Of 111 enrollees, 92 patients (esophageal, 35%; gastroesophageal junction, 25%; gastric, 40%) provided PRO data at baseline plus at least the first 2 weeks of treatment. More than 55% of patients were in the high-severity group for fatigue, lack of appetite, numbness/tingling, and drowsiness, and more than 33% were in the high-severity symptom for inability to eat, nausea, pain, and disturbed sleep. A composite score of these 8 symptoms (45% in the high-severity symptom group; mean 4.5, median 4.4) was associated with poorer quality of life.
Conclusion:
In this real-world longitudinal study, 45% of patients with advanced UGI reported 8 disease- or treatment-specific symptoms that were persistently more severe over time. This provides a rationale for implementing ePRO-based routine assessment and management of this patient cohort during systemic therapy, especially during the first 12 weeks of treatment.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:21Cancer Survival Analysis
01:17Assessment of the Gastrointestinal System I: Subjective Data
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...